Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

Also called NCT01872039

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 163 participants (enrolled count) (from the registry)
Sponsor
Astellas Pharma China, Inc. (from the registry)
Registry
  • NCT NCT01872039
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01872039. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients
Condition
Hypertension Emergency
Condition
End-organ Damage
Intervention (Drug)
Perdipine injection
Lead sponsor
Astellas Pharma China, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01872039
Content hash
e88fc01542a38d4182d9213874306908b1a33cda446fc49f131015742a86147f